Relmada Therapeutics公司股价在盘前交易中大幅上涨27%,报收于5.66美元。这一显著涨幅源于其针对膀胱癌的试验性药物在中期研究阶段公布了积极数据,展现出良好的治疗潜力。
Relmada Therapeutics公司股价在盘前交易中大幅上涨27%,报收于5.66美元。这一显著涨幅源于其针对膀胱癌的试验性药物在中期研究阶段公布了积极数据,展现出良好的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.